Table 1 Patient characteristics.
Metastatic cancer patients | CRPCa | MBC | mCRC | NSCLC |
|---|---|---|---|---|
Number of patients | 190 | 179 | 450 | 137 |
Age (years) | ||||
Median (range) | 70 (49–92) | 59 (27–86) | 63 (27–83) | 65 (29–83) |
Gender | ||||
Male | 190 (100%) | 0 (0%) | 271 (60%) | 74 (54%) |
Female | 0 (0%) | 179 (100%) | 179 (40%) | 63 (46%) |
Unknown | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
ECOG performance status | ||||
0 | 87 (46%) | 83 (46%) | 286 (64%) | 78 (57%) |
1 | 80 (42%) | 73 (41%) | 153 (34%) | 49 (36%) |
2 | 17 (9%) | 17 (10%) | 2 (0%) | 5 (4%) |
3 | 0 (0%) | 1 (1%) | ||
4 | 0 (0%) | 0 (0%) | ||
Unknown | 6 (3%) | 5 (3%) | 9 (2%) | 5 (4%) |
Line of therapy | ||||
1 | 132 (70%) | 75 (42%) | 450 (100%) | 36 (26%) |
2 | 29 (15%) | 27 (15%) | 21 (15%) | |
3+ | 29 (15%) | 75 (42%) | 80 (59%) | |
Unknown | 2 (1%) | |||
Therapy type started after blood draw | ||||
Chemotherapy | 11 (6%) | 75 (42%) | 32 (23%) | |
Hormone | 45 (25%) | |||
Molecular | 8 (4%) | 20 (15%) | ||
Immunotherapy | 80 (58%) | |||
Other | 1 (1%) | |||
Chemotherapy/hormone | 126 (66%) | 11 (6%) | ||
Chemotherapy/molecular | 23 (13%) | 450 (100%) | ||
Chemotherapy/other | 7 (4%) | 1 (1%) | ||
Hormone/molecular | 8 (4%) | |||
Chemotherapy/molecular/hormone | 2 (1%) | |||
Chemotherapy/hormone/other | 45 (24%) | |||
Unknown | 1 (1%) | 5 (3%) | 5 (4%) | |
Follow-up time (in months), median (min–max) | ||||
Alive | 30.4 (1.9–39.0) | 20.6 (1.3–48.8) | 20.2 (0.0–34.0) | 8.8 (0.7–30.1) |
Dead | 11.6 (0.7–39.3) | 9.9 (0.4–31.7) | 12.2 (0.4–32.3) | 4.6 (0.7–25.3) |
Status at last follow-up | ||||
Alive | 53 (28%) | 77 (43%) | 194 (43%) | 68 (50%) |
Dead | 137 (72%) | 102 (57%) | 256 (57%) | 69 (50%) |
